These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8822588)

  • 61. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers.
    Demolis JL; Robert A; Mouren M; Funck-Brentano C; Jaillon P
    J Cardiovasc Pharmacol; 1993 Nov; 22(5):711-6. PubMed ID: 7506323
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina.
    Sakata K; Hoshino T; Yoshida H; Kaburagi T; Takada A
    Cardiovasc Drugs Ther; 1995 Aug; 9(4):601-7. PubMed ID: 8547211
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of prostacyclin and beraprost on ciliary motility of rabbit airway epithelium.
    Tamaoki J; Sakai S; Chiyotani A; Takeyama K; Tagaya E; Konno K
    Pharmacology; 1994 Mar; 48(3):194-200. PubMed ID: 8153147
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prostacyclin inhibits the production of MMP-9 induced by phorbol ester through protein kinase A activation, but does not affect the production of MMP-2 in Human cultured mesangial cells.
    Kitahara M; Ichikawa M; Kinoshita T; Shiozawa S; Shigematsu H; Komiyama A
    Kidney Blood Press Res; 2001; 24(1):18-26. PubMed ID: 11174002
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM.
    Nishimura M; Nozaki O; Nakano H; Tsuchida H; Yamada K
    J Diabetes Complications; 1995; 9(4):330-3. PubMed ID: 8573759
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates lipopolysaccharide-induced cellular injury in lung alveolar epithelial cells.
    Vicil S; Erdoğan S
    Turk J Med Sci; 2015; 45(2):284-90. PubMed ID: 26084116
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cytoprotective action of beraprost sodium against peroxide-induced damage in vascular endothelial cells.
    Kainoh M; Nishio S; Nakadate T
    Pharmacology; 1992; 45(2):61-70. PubMed ID: 1523215
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.
    Fujitani K; Kambayashi J; Murata K; Yano Y; Shinozaki K; Yukawa M; Sakon M; Murata T; Kawasaki T; Shiba E
    Pharmacol Res; 1995 Feb; 31(2):121-5. PubMed ID: 7596955
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effects of beraprost Na, a stable prostacyclin analog, on animal models of stroke.
    Hirano T; Yamori Y; Kanai N; Umetsu T; Nishio S
    Mol Chem Neuropathol; 1992 Aug; 17(1):91-102. PubMed ID: 1388452
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator.
    Ishii K; Usui S; Sugimura Y; Yamamoto H; Yoshikawa K; Hiran K
    Biol Pharm Bull; 2001 Feb; 24(2):188-90. PubMed ID: 11217090
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rapid identification of urokinase plasminogen activator inhibitors from Traditional Chinese Medicines based on ultrafiltration, LC-MS and in silico docking.
    Li L; Kong J; Yao CH; Liu XF; Liu JH
    J Pharm Biomed Anal; 2019 Feb; 164():241-248. PubMed ID: 30396051
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model.
    Yamada M; Sasaki R; Sato N; Suzuki M; Tamura M; Matsushita T; Kurumatani H
    Eur J Pharmacol; 2002 Aug; 449(1-2):167-76. PubMed ID: 12163121
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes.
    Yamagishi S; Amano S; Inagaki Y; Okamoto T; Takeuchi M; Makita Z
    Mol Med; 2002 Sep; 8(9):546-50. PubMed ID: 12456993
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-Substituted-5-halo-2-pyridinyl)guanidines.
    Barber CG; Dickinson RP
    Bioorg Med Chem Lett; 2002 Jan; 12(2):185-7. PubMed ID: 11755350
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines.
    Barber CG; Dickinson RP; Horne VA
    Bioorg Med Chem Lett; 2002 Jan; 12(2):181-4. PubMed ID: 11755349
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effect of Beraprost sodium on the survival of subcutaneous transferred jejunum after vascular pedicle interruption in a rat model.
    Alexandrou K; Hata Y; Matsuka K; Ito O; Matsuda H; Furuichi H; Ishizu N
    J Reconstr Microsurg; 1996 Jan; 12(1):39-46. PubMed ID: 8618225
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Establishment of a new human lymphoma line that secretes plasminogen activator.
    Kubonishi I; Niiya K; Miyoshi I
    Jpn J Cancer Res; 1985 Jan; 76(1):12-5. PubMed ID: 3918906
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced Runx2 ubiquitination.
    Zheng HL; Xu WN; Zhou WS; Yang RZ; Chen PB; Liu T; Jiang LS; Jiang SD
    Cell Death Dis; 2021 May; 12(5):497. PubMed ID: 33993186
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation.
    Tsutsui K; Shirasaki F; Takata M; Takehara K
    Dermatology; 1996; 192(2):120-4. PubMed ID: 8829492
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue.
    Utsunomiya Y; Ogura M; Kawamura T; Mitarai T; Maruyama N; Sakai O
    Clin Exp Immunol; 1995 Mar; 99(3):454-60. PubMed ID: 7882569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.